Biovail Announces Senior Executive Appointments.Business Editors, Health Writers TORONTO, Canada--(BW HealthWire)--May 30, 2000 Biovail Corporation announced today the appointment of two senior members of management. Brian H. Crombie has been appointed as Senior Vice President and Chief Financial Officer of Biovail and Michel P. Chouinard has been appointed Vice President and General Manager of the Company's Crystaal Division in Canada. Mr. Crombie was most recently Managing Director, Corporate Finance of The Jim Pattison Group The Jim Pattison Group is Canada’s 3rd largest privately held company and, in a recent survey by the Financial Post, The Jim Pattison Group was ranked as Canada’s 48th largest company. , one of Canada's largest private conglomerates with over $5 billion in revenues and 50 diverse operating companies. Prior to his involvement in The Jim Pattison Group, Mr. Crombie held a number of senior executive positions with The Molson Companies, the most recent being Senior Vice President Corporate Finance. As well, Mr. Crombie gained strategic financial experience previously at The Walt Disney Noun 1. Walt Disney - United States film maker who pioneered animated cartoons and created such characters as Mickey Mouse and Donald Duck; founded Disneyland (1901-1966) Disney, Walter Elias Disney Company and at Morgan Stanley  To comply with Wikipedia's , the introduction of this article needs a complete rewrite. &
Company.
Mr. Chouinard was most recently Vice President, Commercial Operations, Vaccines at Biochem Pharma Inc., one of Canada's leading pharmaceutical companies. In addition, Mr. Chouinard gained valuable commercial leadership experience through progressively senior positions held with Abbott Laboratories Abbott Laboratories (NYSE: ABT) is a diversified pharmaceuticals and health care company. It has over 65,000 employees and operates in 130 countries. The corporate headquarters are in Abbott Park, Illinois, a neighborhood of North Chicago, Illinois. (Canada) Inc., Glaxo (Canada) and the Lederle Pharmaceutical Division of American Cyanamid American Cyanamid was a large, diversified, American chemical manufacturer. Lederle Laboratories, maker of Centrum and Stresstabs vitamins, was Cyanamid's pharmaceutical division. Davis & Geck was the company's medical device division. Corporation. Mr. Eugene Melnyk Eugene Melnyk (born May 27, 1959 in Toronto, Ontario) is a Canadian businessman of Ukrainian origin who now resides in Barbados. He is the chairman and chief executive officer of Biovail Corporation. , Chairman of the Board, commented "these senior appointments are reflective of Biovail's dramatic growth, both in terms of size and complexity. The executive changes we have made will allow us to more aggressively take advantage of the next phase of our growth through the expansion of our executive resource base and the specialized experience brought to the Company by our new management members." Mr. Kenneth Howling will continue in the role of Vice President Finance. Mr. Rob Harris, previous Vice President and General Manager of Crystaal has been appointed Vice President Business Development where he will be responsible for the acquisition of new product and technology opportunities for Biovail. Biovail Corporation International is an international full-service pharmaceutical company, engaged in the formulation, clinical testing, registration and manufacture of drug products utilizing advanced drug delivery technologies. "Safe Harbor Safe Harbor 1. A legal provision to reduce or eliminate liability as long as good faith is demonstrated. 2. A form of shark repellent implemented by a target company acquiring a business that is so poorly regulated that the target itself is less attractive. " statement under the Private Securities Litigation Reform Act The Private Securities Litigation Reform Act of 1995 (PSLRA) implemented several significant substantive changes affecting certain cases brought under the federal securities laws, including changes related to pleading, discovery, liability, class representation and awards fees and of 1995. To the extent any statements made in this release contain information that is not historical, these statements are essentially forward looking and are subject to risks and uncertainties, including the difficulty of predicting FDA FDA abbr. Food and Drug Administration FDA, n.pr See Food and Drug Administration. FDA, n.pr the abbreviation for the Food and Drug Administration. approvals, acceptance and demand for new pharmaceutical products, the impact of competitive products and pricing, new product development and launch, reliance on key strategic alliances, availability of raw materials, the regulatory environment, fluctuations in operating results and other risks detailed from time to time in the company's filings with the Securities and Exchange Commission. |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion